T1	Outcomes 189 228	angiogenesis-targeted sunitinib therapy
T2	Outcomes 574 590	overall survival
T3	Outcomes 627 658	progression-free survival (PFS)
T4	Outcomes 957 966	median OS
T5	Outcomes 1127 1130	PFS
T6	Outcomes 1277 1341	Toxicity and rates of discontinuations because of adverse events
T7	Outcomes 1453 1460	fatigue
T8	Outcomes 1472 1480	asthenia
T9	Outcomes 1496 1514	hand-foot syndrome
T10	Outcomes 1564 1589	hematologic abnormalities
T11	Outcomes 1595 1606	lymphopenia
T12	Outcomes 1620 1626	anemia
T13	Outcomes 1642 1653	neutropenia
T14	Outcomes 1734 1736	OS
